

## CBL Polyclonal Antibody

Catalog No. E-AB-30783

**Note:** Centrifuge before opening to ensure complete recovery of vial contents.


### Description

|                     |   |
|---------------------|---|
| <b>Reactivity</b>   | Human,Mouse,Rat   |
| <b>Immunogen</b>    | Synthesized peptide derived from human Cbl around the non-phosphorylation site of Y700. |
| <b>Host</b>         | Rabbit  |
| <b>Isotype</b>      | IgG   |
| <b>Purification</b> | Affinity purification   |
| <b>Buffer</b>       | PBS with 0.02% sodium azide,0.5% protective protein and 50% glycerol pH 7.4.            |

### Applications Recommended Dilution

|              |              |
|--------------|--------------|
| <b>WB</b>    | 1:500-1:2000 |
| <b>IHC</b>   | 1:100-1:300  |
| <b>IF</b>    | 1:200-1:1000 |
| <b>ELISA</b> | 1:5000       |

### Data



Western Blot analysis of 293 cells with Cbl Polyclonal Antibody.

**Observed Mw:100kDa**  
**Calculated Mw:100kDa**

### Preparation & Storage

**Storage** Store at -20°C. Avoid freeze / thaw cycles.

### Background

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder

### For Research Use Only